Company news

Sangamo Therapeutics, Inc. news in 2026

Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program

October 13, 2026

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

June 8, 2026

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

May 10, 2026

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

April 30, 2026

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

April 29, 2026

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

March 29, 2026

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

March 18, 2026

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

March 8, 2026

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

February 3, 2026

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

February 3, 2026

Calls in 2026

Decks in 2026